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Abstract
Background:  In experimental models of diabetes mellitus, aggravation of renal injury by
concomitant hypertension has been described. Inflammatory mechanisms contribute to renal
damage in both diseases. We investigated whether hypertension and diabetes mellitus act
synergistically to induce macrophage infiltration and matrix expansion in the kidney.
Methods:  Insulin-dependent diabetes mellitus was induced by streptozotocin injections to
hypertensive mRen2-transgenic rats (TGR) and normotensive Sprague-Dawley control rats.
Quantitative immunohistochemical examination of kidney tissue sections was used to measure
macrophage infiltration and matrix expansion. The expression of MCP-1, Osteopontin, RANTES,
ICAM-1 and VCAM-1 was evaluated by real-time RT-PCR. The localization of MCP-1 was studied
by immunohistochemistry.
Results:  Macrophage infiltration was present in the kidney of normotensive diabetic rats.
Hypertensive rats exhibited a more marked infiltration of macrophages, regardless of whether
diabetes was present or not. Gene expression of ICAM-1, VCAM-1 and RANTES was unaltered
whereas Osteopontin and MCP-1 were induced by hypertension. Immunoreactive MCP-1 was
slightly increased in diabetic rat kidney podocytes, and more markedly increased in hypertensive
animals. Glomerular matrix accumulation was induced by diabetes and hypertension to a similar
degree, and was highest in hypertensive, diabetic animals.
Conclusion: Diabetes mellitus caused a mild, and angiotensin-dependent hypertension a more
marked infiltration of macrophages in the kidney. Combination of both diseases led to additive
effects on matrix expansion but not on inflammation. Hypertension appears to be a much stronger
stimulus for inflammation of the kidney than STZ diabetes, at least in mRen2-transgenic rats.
Published: 27 May 2005
BMC Nephrology 2005, 6:6 doi:10.1186/1471-2369-6-6
Received: 18 October 2004
Accepted: 27 May 2005
This article is available from: http://www.biomedcentral.com/1471-2369/6/6
© 2005 Hartner et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Nephrology 2005, 6:6 http://www.biomedcentral.com/1471-2369/6/6
Page 2 of 10
(page number not for citation purposes)
Background
Diabetic nephropathy is the most common cause of end-
stage renal failure in developed countries and its inci-
dence continues to rise [1]. In most patients with diabetic
nephropathy, hypertension is present and contributes sig-
nificantly to the progression of renal failure in diabetes
[1]. Studies in diabetic rats as well as in human volunteers
with hyperglycemia indicated that activation of the intra-
renal renin-angiotensin system (RAS) plays a key role in
the development of the hemodynamic abnormalities in
early diabetic nephropathy [2]. Angiotensin II-induced
hypertension leads to macrophage infiltration in the kid-
ney, and chemokines have been proposed as mediators of
macrophage infiltration [3,4]. For example, the chemok-
ine monocyte chemoattractant protein-1 (MCP-1) can be
induced in vascular smooth muscle cells by angiotensin II
[5]. The finding that MCP-1 is likewise induced in renal
mesangial cells by high glucose concentrations [6] is in
keeping with the hypothesis that chronic inflammatory
mechanisms may also contribute to the pathogenesis of
diabetic nephropathy [7]. Thus, induction of chemokines
in the diabetic kidney seems to enhance macrophage infil-
tration [8-12].
Kelly et al. described that induction of osteopontin is
related to macrophage infiltration in streptozotocin dia-
betic, mRen-2 transgenic hypertensive rats [13]. These
authors had previously reported that this animal model
resembles aspects of human diabetic nephropathy [14].
We used this animal model to examine the potential con-
tribution of other chemokines (MCP-1, RANTES) and
adhesion molecules to macrophage infiltration. Further,
we sought to delineate the relative contribution of angi-
otensin-dependent hypertension from that of diabetes to
inflammation by including normotensive diabetic rats of
the same genetic background.
Methods
Rat models of hypertension and diabetes mellitus
Rats were housed in a room maintained at 22 ± 2°C,
exposed to a 12 hour dark/light cycle. The animals were
allowed unlimited access to chow (#1320, Altromin, Lage,
Germany) and tap water. All procedures performed on
animals were done in accordance with guidelines of the
American Physiological Society and were approved by the
local government authorities (Regierung von Mittelf-
ranken, AZ # 621-2531.31-19/96). Eighteen male rats het-
erozygous for the mouse ren-2 transgene (TGR) with
angiotensin II dependent hypertension [15] and 18 age-
matched Sprague-Dawley-Hannover (SD) controls (Möl-
legaard, Eijby, Denmark) at an average body weight of
250 g were used for induction of diabetes by intraperito-
neal injection of streptozotocin (STZ) (Sigma, Deisen-
hofen, Germany) (70 mg per kg of body weight) dissolved
in 0.1 M sodium citrate buffer (pH 4.5). Two days later,
blood was obtained from the tail vein and diabetes was
confirmed by measurement of blood glucose using a
reflectance meter (Glucometer Elite II, Bayer, Leverkusen,
Germany). Only rats with a consistent blood glucose >
250 mg/dl were included (13 TGR and 12 SD). Diabetic
and control rats were followed for 5 weeks. Blood glucose
and systolic blood pressure (as measured by tail-cuff
plethysmography under light ether anesthesia) were mon-
itored weekly (at 8 a.m.). After five weeks, the rats were
kept in metabolic cages for determination of urinary albu-
min excretion (enzyme immunoassay kit, CellTrend,
Luckenwalde, Germany) for 24 hours. Subsequently, the
rats were equipped with a femoral catheter and arterial
blood pressure was measured via transducers (Grass
Instruments, Quincy, USA) connected to a polygraph
(Hellige, Freiburg, Germany) four hours after termination
of anesthesia. Rats were sacrificed and kidneys were
weighed and decapsulated. Half of each kidney was
immediately snap-frozen in liquid nitrogen for later pro-
tein and RNA extraction. The other half was fixed in
methyl-Carnoy solution (60% methanol, 30% chloro-
form and 10% glacial acetic acid) for histology and
immunohistochemistry.
Real-time RT-PCR detection of mRNA
Renal cortical tissue extraction and real-time RT-PCR were
carried out as described [16]. Briefly, first-strand cDNA
was synthesized with TaqMan reverse transcription rea-
gents (Applied Biosystems, Darmstadt, Germany) using
random hexamers as primers. Final RNA concentration in
the reaction mixture was adjusted to 0,5 ng/µL. Reactions
without Multiscribe reverse transcriptase were used as
negative controls for genomic DNA contamination. PCR
was performed with an ABI PRISM 7000 Sequence Detec-
tor System and TaqMan or SYBR Green Universal PCR
Master Mix (Applied Biosystems) according to the manu-
facturers instructions. All samples were run in triplicates.
The relative amount of the specific mRNA was normalized
with respect to 18S rRNA. Primer design was accom-
plished with PrimerExpress software (Applied Biosys-
tems). Primer sequences used are as follows. RANTES
forward primer: GTCGTCTTTGTCACTCGAAGGA,
RANTES reverse primer: GATGTATTCTTGAACCCACT-
TCTTCTC and RANTES probe: CCGCCAAGTGTGTG
CCAACCC. ICAM-1 forward primer: GGGCCCCCTACCT-
TAGGAA, ICAM-1 reverse primer: GGGACAGTGTC-
CCAGCTTTC. VCAM-1 forward primer: TGTGGAAGTGT
GCCCGAAAT, VCAM-1 reverse primer: TGCCTTGCG-
GATGGTGTAC. Primers and probes for 18S, MCP-1 and
osteopontin were previously described [16-18].
Western blot detection of MCP-1
Protein was extracted from kidneys of 5 rats of each group
using Tri-reagent (MRC Inc.). Protein concentration was
determined using a protein assay kit (Pierce, Rockford, IL,BMC Nephrology 2005, 6:6 http://www.biomedcentral.com/1471-2369/6/6
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USA). Western blot analysis was performed as described
before [3] with a polyclonal rabbit anti-rat MCP-1 antise-
rum which was kindly provided by Dr. T. Yoshimura, Fre-
derick, MD and used at a dilution of 1:250.
Immunohistochemistry
After overnight fixation in methyl-Carnoy solution, tis-
sues were dehydrated by bathing in increasing concentra-
tions of methanol, followed by 100% iso-propanol. After
embedding in paraffin, 3 µm sections were cut with a Leitz
SM 2000 R microtome (Leica Instruments, Nussloch, Ger-
many). After deparaffinization, endogenous peroxidase
activity was blocked with 3% H2O2 in methanol for 20
min at room temperature. Immunohistochemical detec-
tion of ED-1 was carried out as described [3]. The mouse
monoclonal antibody against the macrophage marker
ED-1 was purchased from Serotec (Biozol, Eching, Ger-
many) and used at a dilution of 1:250. Renal cortical col-
lagen I was detected by a rabbit polyclonal antibody
(Biogenesis, Poole, England, UK) at a dilution of 1:1000.
A goat polyclonal antibody to collagen IV (Southern Bio-
technology Associates, Birmingham, AL, USA) was used at
a dilution of 1:500. Each slide was counterstained with
hematoxylin.
Analysis of data
Intraglomerular ED-1 positive cells were counted in all
glomeruli of a given kidney section (100–300 glomeruli,
no selection) and expressed as cells per glomerular sec-
tion. Interstitial ED-1 positive cells were counted in 30
medium-power (magnification 250 ×) cortical views per
section and expressed as cells per square mm. Counting
was begun in a random cortical field and in consecutive
non-overlapping cortical fields to the right of the previous
view without selection; if necessary, counting was contin-
ued at the opposite (left) edge of the section. MCP-1 stain-
ing was evaluated in >100 glomeruli and 20 cortical
interstitial low-power (100 ×) fields by a blinded
observer. Glomeruli were classified as showing no stain-
ing (score 0), staining of up to one third of the glomerular
tuft area (score 1), staining affecting one to two thirds
(score 2) or more than two thirds of the glomerular tuft
(score 3). Interstitial fields were classified as showing no
staining (score 0), one area of peritubular interstitial
staining not spanning the circumference of a tubular
cross-section (score 1); two such areas or one area of stain-
ing spanning the circumference of a tubular cross-section
(score 2), peritubular staining involving less than 4 (score
3) or more than 4 (score 4) tubular cross-sections. Expan-
sion of interstitial collagen I was measured by Metaview
software (Visitron Systems, Puchheim, Germany) in 10
non-overlapping medium-power cortical views per sec-
tion excluding glomeruli and was expressed as percent of
stained area per cross section. Glomerular collagen IV
staining was measured by Metaview in every third glomer-
ulus per cross section, and the stained area was expressed
as percentage of the total area of the glomerular tuft.
Two-way analysis of variance, followed by the post-hoc
Bonferroni test with adjustment for multiple comparison,
Blood glucose (panel A), arterial blood pressure (panel B)  and albuminuria (panel C) of diabetic and hypertensive rats Figure 1
Blood glucose (panel A), arterial blood pressure (panel B) 
and albuminuria (panel C) of diabetic and hypertensive rats. 
Blood glucose was measured 24 hours before termination of 
the experiment. Mean arterial blood pressure was deter-
mined in awake rats via indwelling catheters inserted into the 
femoral artery. For determination of albuminuria, urine was 
collected 24 hours before sacrifice. SD, normotensive nor-
moglycemic control rats; TGR, transgenic hypertensive rats; 
STZ, streptozotocin treatment. * indicates p < 0.05 versus 
normotensive normoglycemic SD control rats.BMC Nephrology 2005, 6:6 http://www.biomedcentral.com/1471-2369/6/6
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was used to compare groups. A p value < 0.05 was consid-
ered significant. The procedures were carried out using the
SPSS version 11.5 software (SPSS Inc., Chicago, IL, USA).
Values are displayed as means ± standard error of the
mean.
Results
Injection of STZ induced diabetes mellitus equally well in
SD and in TGR. In STZ-treated animals, blood glucose lev-
els were not different between TGR and SD throughout
the development of the disease (see figure 1A). In
untreated TGR, blood glucose did not differ from
untreated SD rats (figure 1A). Systolic and mean arterial
blood pressure were significantly higher in TGR compared
to SD (figure 1B). Development of hypertension was not
affected by STZ treatment; there were no differences
between STZ-treated and untreated control animals with
regard to systolic blood pressure (data not shown) and
mean intraarterial blood pressure measurements (figure
1B). Albumin excretion was increased in diabetic animals
and even more in hypertensive rats; combination of both
diseases did not further elevate albuminuria (figure 1C).
STZ diabetes led to reduced body weight gain and kidney
hypertrophy. Kidney weight/body weight ratio was signif-
icantly increased in SD-STZ, TGR and TGR-STZ versus SD
controls as well as in TGR-STZ versus TGR (table 1). TGR
hypertensive animals had significantly higher heart
weight/body weight ratios than normotensive SD rats,
which was not affected by STZ diabetes (table 1). Diabetes
led to polyuria (table 1), which was further increased in
hypertensive rats. Urine production was slightly higher in
TGR than in SD, but significantly elevated in the diabetic
groups SD-STZ and TGR-STZ (table 1).
Both, diabetes and hypertension caused macrophage infil-
tration of the kidney (figure 2). The effect of hypertension,
however, was more pronounced. TGR-STZ animals had
the highest levels of macrophages in glomeruli but there
was no statistically significant difference compared to
TGR (figure 2). Minor macrophage infiltration was
observed in the interstitial space of SD-STZ rats with dia-
betes alone while marked macrophage influx was noted in
glomeruli of normoglycemic hypertensive TGR (figure 2).
In the combined model of diabetes and hypertension in
TGR-STZ, the effect of both diseases on macrophage infil-
tration of the interstitial space appeared to be additive
although the numerical difference between TGR and TGR-
STZ failed to reach statistical significance (figure 2). Of
note, in TGR-STZ rats, interstitial macrophages were often
localized in periglomerular areas (not shown).
Expression of mediators regulating macrophage infiltra-
tion (MCP-1, osteopontin, RANTES) and adhesion mole-
Table 1: Body weight, organ weights and urine production
Group SD SD+STZ TGR TGR+STZ
N 57 7 6
Body weight (g) 429.6 ± 9.0 308.0 ± 9.5 * 388.3 ± 14.6 * 316.3 ± 36.4 * §
Heart weight (g) 1.53 ± 0.06 1.24 ± 0.05 * 1.94 ± 0.06 * 1.47 ± 0.18
Heart weight / body weight ratio(mg/g) 3.55 ± 0.11 4.03 ± 0.09 * 5.03 ± 0.19 * 4.63 ± 0.16 *
Kidney weight (g) 1.30 ± 0.03 1.53 ± 0.02 * 1.47 ± 0.06 * 1.67 ± 0.13 *
Kidney weight / body weight ratio(mg/g) 3.04 ± 0.05 4.98 ± 0.15 * 3.82 ± 0.18 * 5.43 ± 0.33 * §
Urine production (ml/24 h) 22.0 ± 2.7 95.7 ± 10.1 * 30.0 ± 1.7 * 111.5 ± 13.6 * §
* p < 0.05 versus SD
§p < 0.05 versus TGR
Table 2: mRNA expression of the chemokine RANTES and the adhesion molecules ICAM-1 and VCAM-1.
SD SD-STZ TGR TGR-STZ
RANTES 1.0 ± 0.26 0.57 ± 0.03 0.47 ± 0.07 0.6 ± 0.12
VCAM-1 1.0 ± 0.14 0.98 ± 0.33 1.34 ± 0.51 0.65 ± 0.16
ICAM-1 1.0 ± 0.25 1.31 ± 0.49 0.95 ± 0.32 0.68 ± 0.23
Data are fold induction relative to SD as assessed by real-time RT-PCR from renal cortex and are displayed as mean ± standard error of the mean. 
SD Sprague-Dawley Hannover rats. STZ streptozotocin-treated. TGR Ren-2 transgenic rats. There were no significant differences.BMC Nephrology 2005, 6:6 http://www.biomedcentral.com/1471-2369/6/6
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cules involved in macrophage infiltration (ICAM-1,
VCAM-1) was investigated to further elucidate inflamma-
tory pathways in hypertensive and diabetic renal disease:
In TGR rats, renal MCP-1 and osteopontin mRNA steady
state levels were increased compared to SD controls, as
determined by real-time RT-PCR (figure 3A and 3B). STZ-
induced diabetes mellitus of five weeks did not signifi-
cantly increase MCP-1 and osteopontin mRNA in SD rats
and did not augment the upregulation of MCP-1 mRNA
in TGR (figure 3). In contrast, the chemokine RANTES or
the adhesion molecules ICAM-1 and VCAM-1 were not
transcriptionally regulated in the kidney in response to
hypertension or diabetes (table 2). The expression level of
MCP-1 correlated with macrophage counts in the intersti-
tial space (r2 = 0.47, p = 0.002) but not in glomeruli (r2 =
0.002, p = 0.857).
The specificity of the antibody to MCP-1 was confirmed
by Western blot analysis of renal protein (figure 4) yield-
ing a characteristic double band. By immunohistochemis-
try (figure 5), staining of the smooth muscle layer of small
arteries and afferent arterioles was present in controls as
well as in diseased animals, albeit more markedly in
hypertensive rats (figure 5C). However, almost no
glomerular MCP-1 staining was observed in control ani-
mals (figure 5A). Focal and segmental positive staining for
MCP-1 was detected in glomeruli of normotensive SD-
STZ rats with diabetes mellitus (figure 5B). Widespread
glomerular staining for MCP-1 (figure 5C and 5D) was
seen in TGR and TGR-STZ. By high power light micros-
copy and double-staining for ED-1, it was noted that
intrinsic glomerular cells, rather than infiltrating cells,
stained positively for MCP-1. The pattern of immunos-
taining suggested a predominantly podocyte and occa-
sionally endothelial localization of MCP-1 (figure 5). In
the cortical interstitium, MCP-1-staining was localized to
peritubular spindle-shaped interstitial cells, possibly
fibroblasts, in close proximity to ED-1-positive macro-
phages (figure 5E). Quantification of glomerular and
interstitial MCP-1 staining demonstrated a mild increase
in SD-STZ rats and a massive increase in TGR and TGR-
STZ (figure 6A). Interstitial staining was little affected by
STZ diabetes but markedly induced by TGR hypertension
(figure 6B).
A moderate matrix expansion was detected in SD-STZ rats
in the renal cortex (figure 7A) and in glomeruli (figure 7B)
as compared to SD. In TGR, cortical and glomerular
matrix expansion was more prominent than in STZ (figure
7A+B), which was further aggravated in TGR-STZ with
regard to glomerular matrix (figure 7B) but not to cortical
matrix expansion (figure 7A).
Discussion
The results of the present study confirm that in the rat,
both hypertension and diabetes mellitus induce macro-
phage infiltration in the kidney which may contribute to
the development of glomerular and interstitial injury.
Moreover, our results confirm and extend previous reports
of increased MCP-1 expression in the kidney in diabetes
[8-12] and in hypertension [3]. In our study, the effect of
hypertension on MCP-1 and osteopontin expression as
well as on macrophage infiltration was much more prom-
inent than the effects of diabetes mellitus. Streptozotocin
diabetes induced some predominantly glomerular MCP-1
Macrophage infiltration of glomeruli (panel A) and interstitial  space (panel B) of the kidney from rats with diabetes mellitus  and/or hypertension Figure 2
Macrophage infiltration of glomeruli (panel A) and interstitial 
space (panel B) of the kidney from rats with diabetes mellitus 
and/or hypertension. Glomerular macrophages are 
expressed as ED-1-positive cells per glomerular cross-sec-
tion, interstitial macrophages as ED-1-positive cells per 
square mm. SD, normotensive normoglycemic control rats; 
TGR, transgenic hypertensive rats; STZ, streptozotocin 
treatment. Data are mean ± SEM of n = 5 rats. * indicates p < 
0.05 versus normotensive normoglycemic SD control rats.BMC Nephrology 2005, 6:6 http://www.biomedcentral.com/1471-2369/6/6
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expression and macrophage infiltration whereas hyper-
tensive rats exhibited marked interstitial and glomerular
inflammation. This finding cannot be explained by the
longer duration of hypertension, compared with diabetes.
In preliminary experiments (data not shown), we assured
that macrophage infiltration in the kidney is highest from
2 to 6 weeks after STZ injection and decreases thereafter,
as described previously by others [7,12]. A different time
course of macrophage influx, with a prominent late infil-
tration, has been found in other rodent models of diabe-
tes, for example in db/db mice with type 2 diabetes [11].
Our data did not reveal evidence for a synergistic effect of
TGR hypertension and STZ diabetes on kidney inflamma-
tion. Macrophage infiltration tended to slightly higher
values in hypertensive, hyperglycemic rats, compared to
hypertensive, normoglycemic animals but this trend did
not reach statistical significance. These results contrast
sharply with those reported by Kelly et al. [13] who
described very little inflammation in normoglycemic TGR
but a very marked macrophage infiltration in diabetic
TGR. We cannot fully explain this discrepancy but several
factors may contribute to it. Kelly et al. did not include
normotensive controls, neither normoglycemic nor
hyperglycemic [13]. Therefore, these authors may have
missed the effect of TGR hypertension alone on macro-
phage infiltration. The shorter duration of diabetes in our
study is unlikely to explain the different findings, as dis-
cussed above, but the different age and gender of the rats
may play a role. We induced STZ diabetes in adult male
TGR whereas Kelly et al. employed adolescent (6 week
old) female TGR [13]. In other respects, our data con-
firmed the notion that TGR hypertension aggravates the
renal sequelae of STZ diabetes, as described by Kelly et al.
[14]. Glomerular sclerosis, as assessed by quantification
of collagen IV staining, was significantly higher in hyper-
tensive, diabetic TGR, compared to all other groups.
Real-time RT-PCR was used to screen for large differences
of the expression of several proinflammatory molecules,
and we focused on the factors which exhibited a clear
induction in diabetic, hypertensive TGR. The apparently
"negative" results on ICAM-1, VCAM-1 and RANTES
should not be misinterpreted to exclude a role of these
factors. A more subtle investigation might have shown
localized induction of these factors which has in fact been
Real-time RT-PCR analysis of MCP-1 (A) and osteopontin (B)  mRNA expression in the renal cortex Figure 3
Real-time RT-PCR analysis of MCP-1 (A) and osteopontin (B) 
mRNA expression in the renal cortex. Data are expressed as 
fold control compared to SD control rats. Data are mean ± 
SEM of n = 5 rats. * indicates p < 0.05 versus normotensive 
normoglycemic SD control rats. SD, normotensive normo-
glycemic control rats; TGR, transgenic hypertensive rats; 
STZ, streptozotocin treatment.
Western blot analysis for MCP-1 protein in cortical protein  preparations of two rats of each experimental group, yielding  the characteristic MCP-1 double band (14 and 16 kDa) Figure 4
Western blot analysis for MCP-1 protein in cortical protein 
preparations of two rats of each experimental group, yielding 
the characteristic MCP-1 double band (14 and 16 kDa). SD, 
normotensive normoglycemic control rats; TGR, transgenic 
hypertensive rats; STZ, streptozotocin treatment.BMC Nephrology 2005, 6:6 http://www.biomedcentral.com/1471-2369/6/6
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described in hypertensive and/or diabetic kidney disease
[4,12,19,20]. The most prominent induction was detected
for osteopontin and MCP-1. We focused on MCP-1
because the expression of osteopontin in the diabetic TGR
had already been investigated by Kelly et al. [13]. Real-
time RT-PCR did not detect an induction of MCP-1 in
total cortical RNA of kidney of normotensive, diabetic
rats. However, a more subtle investigation by means of
immunohistochemistry clearly showed that MCP-1 was
increased in glomeruli of normotensive, diabetic rats, in
agreement with previous reports [8-12]. MCP-1 was more
markedly induced in hypertensive rats but the effects of
hypertension and diabetes were not additive. Interest-
ingly, glomerular MCP-1 was localized in podocytes, sim-
ilar to the localization of osteopontin in glomeruli of
diabetic TGR described by Kelly et al. [13]. These findings
underscore the potential role of podocytes for glomerular
inflammation.
Conclusion
In our rat model, the effects of hypertension and/or angi-
otensin II on the expression of the chemokine MCP-1, and
on macrophage infiltration, in the kidney were much
more pronounced than the effects of diabetes. Further-
more, the effects of both diseases combined on kidney
inflammation were not synergistic, and often not even
additive. We speculate that the mechanical or hormonal
factor – i.e., angiotensin-dependent hypertension – plays
a much greater role for the induction of an inflammatory
reaction in the kidney than does the metabolic factor,
hyperglycemia. In patients with diabetic nephropathy, the
decisive contribution of hypertension to renal damage has
often been noted [1,21]. Investigators have combined STZ
diabetes with genetic models of hypertension, and accel-
eration of diabetic nephropathy was reported regardless of
whether spontaneously hypertensive rats [22], Dahl salt-
sensitive rats [23] or mRen2-transgenic hypertensive TGR
[14] were used. Our data do not support the notion that
inflammation explains this acceleration of diabetic kidney
damage because chemokine expression and macrophage
infiltration were largely determined by the presence of
hypertension, regardless of whether the animals were dia-
betic or normoglycemic. Other processes, for example
accumulation of extracellular matrix, could contribute to
the accelerated kidney damage caused by diabetes melli-
tus in combination with hypertension.
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Matrix expansion in the renal cortex and the glomerulus Figure 7
Matrix expansion in the renal cortex and the glomerulus. A: 
measurement of cortical collagen I staining and B: measure-
ment of glomerular collagen IV staining. Data are mean ± 
SEM, * indicates p < 0.05 versus normotensive normoglyc-
emic SD controls. # indicates p < 0.05 versus SD-STZ. § indi-
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